Literature DB >> 24525589

Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.

Aaron T Wecksler1, Sung Hee Hwang, Hiromi I Wettersten, Jennifer E Gilda, Amy Patton, Leonardo J Leon, Kermit L Carraway, Aldrin V Gomes, Keith Baar, Robert H Weiss, Bruce D Hammock.   

Abstract

In the current work, we carried out a mechanistic study on the cytotoxicity of two compounds, trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-N-methyl-benzamide (t-AUCMB) and trans-N-methyl-4-{4-[3-(4-trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzamide (t-MTUCB), that are structurally similar to sorafenib. These compounds show strong cytotoxic responses in various cancer cell lines, despite significant differences in the induction of apoptotic events such as caspase activation and lactate dehydrogenase release in hepatoma cells. Both compounds induce autophagosome formation and LC3I cleavage, but there was little observable effect on mTORC1 or the downstream targets, S6K1 and 4E-binding protein. In addition, there was an increase in the activity of upstream signaling through the IRS1/PI3K/Akt-signaling pathway, suggesting that, unlike sorafenib, both compounds induce mammalian target of rapamycin (mTOR)-independent autophagy. The autophagy observed correlates with mitochondrial membrane depolarization, apoptosis-inducing factor release, and oxidative stress-induced glutathione depletion. However, there were no observable changes in the endoplasmic reticulum-stress markers such as binding immunoglobulin protein, inositol-requiring enzyme-α, phosphorylated eukaryotic initiation factor 2, and the lipid peroxidation marker, 4-hydroxynonenal, suggesting endoplasmic reticulum-independent oxidative stress. Finally, these compounds do not have the multikinase inhibitory activity of sorafenib, which may be reflected in their difference in the ability to halt cell cycle progression compared with sorafenib. Our findings indicate that both compounds have anticancer effects comparable with sorafenib in multiple cell lines, but they induce significant differences in apoptotic responses and appear to induce mTOR-independent autophagy. t-AUCMB and t-MTUCB represent novel chemical probes that are capable of inducing mTOR-independent autophagy and apoptosis to differing degrees, and may thus be potential tools for further understanding the link between these two cellular stress responses.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24525589      PMCID: PMC3947856          DOI: 10.1097/CAD.0000000000000079

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  44 in total

1.  Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death.

Authors:  N Joza; S A Susin; E Daugas; W L Stanford; S K Cho; C Y Li; T Sasaki; A J Elia; H Y Cheng; L Ravagnan; K F Ferri; N Zamzami; A Wakeham; R Hakem; H Yoshida; Y Y Kong; T W Mak; J C Zúñiga-Pflücker; G Kroemer; J M Penninger
Journal:  Nature       Date:  2001-03-29       Impact factor: 49.962

2.  A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity.

Authors:  T Decker; M L Lohmann-Matthes
Journal:  J Immunol Methods       Date:  1988-11-25       Impact factor: 2.303

3.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

4.  Upregulation of proteasome activity in muscle RING finger 1-null mice following denervation.

Authors:  Aldrin V Gomes; Dave S Waddell; Rylie Siu; Matthew Stein; Shannamar Dewey; J David Furlow; Sue C Bodine
Journal:  FASEB J       Date:  2012-04-16       Impact factor: 5.191

5.  Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.

Authors:  Satoshi Shimizu; Tetsuo Takehara; Hayato Hikita; Takahiro Kodama; Hinako Tsunematsu; Takuya Miyagi; Atsushi Hosui; Hisashi Ishida; Tomohide Tatsumi; Tatsuya Kanto; Naoki Hiramatsu; Naonobu Fujita; Tamotsu Yoshimori; Norio Hayashi
Journal:  Int J Cancer       Date:  2011-09-12       Impact factor: 7.396

6.  IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response.

Authors:  Kyungho Lee; Witoon Tirasophon; Xiaohua Shen; Marek Michalak; Ron Prywes; Tetsuya Okada; Hiderou Yoshida; Kazutoshi Mori; Randal J Kaufman
Journal:  Genes Dev       Date:  2002-02-15       Impact factor: 11.361

7.  Mitophagy is triggered by mild oxidative stress in a mitochondrial fission dependent manner.

Authors:  Magdalena Frank; Stéphane Duvezin-Caubet; Sebastian Koob; Angelo Occhipinti; Ravi Jagasia; Anton Petcherski; Mika O Ruonala; Muriel Priault; Bénédicte Salin; Andreas S Reichert
Journal:  Biochim Biophys Acta       Date:  2012-08-16

8.  Purification and characterization of a Z-Leu-Leu-Leu-MCA degrading protease expected to regulate neurite formation: a novel catalytic activity in proteasome.

Authors:  S Tsubuki; H Kawasaki; Y Saito; N Miyashita; M Inomata; S Kawashima
Journal:  Biochem Biophys Res Commun       Date:  1993-11-15       Impact factor: 3.575

9.  The promoter region of the yeast KAR2 (BiP) gene contains a regulatory domain that responds to the presence of unfolded proteins in the endoplasmic reticulum.

Authors:  K Kohno; K Normington; J Sambrook; M J Gething; K Mori
Journal:  Mol Cell Biol       Date:  1993-02       Impact factor: 4.272

10.  Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.

Authors:  Sung Hee Hwang; Aaron T Wecksler; Guodong Zhang; Christophe Morisseau; Long V Nguyen; Samuel H Fu; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2013-05-15       Impact factor: 2.823

View more
  1 in total

Review 1.  Modulation of Autophagy by Sorafenib: Effects on Treatment Response.

Authors:  Nestor Prieto-Domínguez; Raquel Ordóñez; Anna Fernández; Andres García-Palomo; Jordi Muntané; Javier González-Gallego; José L Mauriz
Journal:  Front Pharmacol       Date:  2016-06-08       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.